Uncategorized

The for-profit operator’s guidance raise is “cautious,” one analyst said. Still, HCA is staring down challenges like the potential expiration of more generous Affordable Care Act subsidies.

Plans found 39% of claims submitted to independent dispute resolution last year were actually ineligible for the process, but arbiters themselves caught only 17% of improper cases, according to AHIP and the BCBSA.

  En un ecosistema informativo saturado, distinguir entre evidencia y espectáculo se ha convertido en un desafío cotidiano. La divulgación científica no sólo consiste en contar hallazgos; también es enseñar a pensar con números: compren …

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that not only lacks a disease-modifying treatment but suffered significant setbacks after a patient died in a clinical trial for Sarepta’s investigational gene therapy.

Mayo Clinic and QAS.AI will receive funding and mentorship to help advance their projects.

Learning and development has proven key to fighting burnout and ensuring the success of the health system’s people managers, Deborah Yount told HR Dive.

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ziclumeran, though analysts at BMO Capital Markets at the time brushed it off as a “non-concern.”

In this deep dive, BioSpace investigates China’s rise as a biotech powerhouse.

Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the longer-term advantages of open heart surgery.